The effect of β-blocker use on cyclosporine level in cardiac transplant recipients

Journal of Heart and Lung Transplantation

Volumn 24, Issue 12, 2005, Pages 2144-2147

  Bader, Feras M ^a   Hagan, Mary E ^b   Crompton, Jason A ^a   Gilbert, Edward M ^a,c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CYCLOSPORIN; CYTOCHROME P450; GLYCOPROTEIN P; METOPROLOL;

ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; FOLLOW UP; HEART TRANSPLANTATION; HUMAN; PRIORITY JOURNAL;

ABSORPTION; ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; CYCLOSPORINE; DRUG INTERACTIONS; HEART TRANSPLANTATION; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; METOPROLOL; P-GLYCOPROTEIN; PROPANOLAMINES; RETROSPECTIVE STUDIES;

EID: 29144485497     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2005.05.002     Document Type: Article

References (17)

1. C. Bracht, X. Yan, H. LaRocca, G. Sütsch, W. Kiowski Cyclosporine A and control of vascular tone in the human forearm influence of post-transplant hypertension J Hypertens 17 1999 357 363
2. E. Ozdogan, N.R. Banner, M. Fitzgerald Factors influencing the development of hypertension following cardiac transplantation J Heart Transplant 5 1990 548 553
3. M.E. Thompson, A.P. Shapiro, A.M. Johnsen The contrasting effects of cyclosporin-A and azathioprine on arterial blood pressure and renal function following cardiac transplantation Int J Cardiol 11 1986 219 229
4. R.G. Luke Mechanism of cyclosporine-induced hypertension Am J Hypertens 5 1991 A79 A84
5. A. Nishiyama, H. Kobori, T. Fukui Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension Hypertension 42 2003 754 760
6. U. Scherrer, S.F. Vissing, B.J. Morgan Cyclosporine-induced sympathetic activation and hypertension after heart transplantation N Engl J Med 323 1990 693 699
7. D. Lucini, R.V. Milani, H.O. Ventura, M.R. Mehra, F. Messerli, M. Pagani Study of arterial and autonomic effects of cyclosporine in humans Hypertension 35 2000 1258 1263
8. M. Kaijser, C. Johnsson, L. Zezina, U. Backman, E. Dimeny, B. Fellstrom Elevation of cyclosporine A blood levels during carvedilol treatment in renal transplant patients Clin Transplant 11 1997 577 581
9. K. Takara, T. Sakaeda, K. Okumura Carvedilol a new candidate for reversal MDR1/P-glycoprotein-mediated multidrug resistance Anticancer Drugs 15 2004 303 309
10. M. Kakumoto, T. Sakaeda, K. Takara Effects of carvedilol of MDR1-mediated multidrug resistance comparison with verapamil Cancer Sci 94 2003 81 86
11. C.J. Matheny, M.W. Lamb, K.L. Brouwer, G.M. Pollack Pharmacokinetic and Pharmacodynamic Implications of P-glycoprotein Modulation Pharmacotherapy 21 2001 778 796
12. A.H. Schinkel, E. Wagenaar, L. van Deemter, C.A. Mol, P. Borst Absence of mdr 1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A J Clin Invest 96 1995 1698 1705
13. A. Lo, G.J. Burckart P-glycoprotein and drug therapy in organ transplantation J Clin Pharmacol 39 1999 995 1005
14. T. Saeki, K. Ueda, Y. Tanigawara, R. Hori, T. Komano Human P-glycoprotein transports cyclosporin A and FK 506 J Biol Chem 268 1993 6077 6080
15. G. Fricker, J. Drewe, J. Huwyler, H. Gutmann, C. Beglinger Relevance of P-glycoprotein for the enteral absorption of cyclosporin A in vitro-in vivo correlation Br J Pharmacol 118 1996 1841 1847
16. K.S. Lown, R.R. Mayo, A.B. Leichtman Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine Clin Pharmacol Ther 62 1997 248 260
17. V.J. Wacher, C.Y. Wu, L.Z. Benet Overlapping substrate specificity and tissue distribution of cytochrome P450 3A and P-glycoprotein implications for drug delivery and activity in cancer chemotherapy Mol Carcinog 13 1995 129 134